Alongside these innovative research fields, approaches based more classically on the use of molecularly targeted drugs capable of modifying the inflammatory pathway of AD, acting on several key molecules, such as IL-1α, IL5, IL17, IL25, TLSP, IL31 and IL33, are being researched. This evidence concerns the gene IL1A and Alzheimer disease.